These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Moussa CE; Wersinger C; Tomita Y; Sidhu A Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920 [TBL] [Abstract][Full Text] [Related]
9. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease. Wu W; Sung CC; Yu P; Li J; Chung KKK PLoS One; 2020; 15(4):e0232019. PubMed ID: 32343709 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Guo JT; Chen AQ; Kong Q; Zhu H; Ma CM; Qin C Cell Mol Neurobiol; 2008 Jan; 28(1):35-47. PubMed ID: 17985233 [TBL] [Abstract][Full Text] [Related]
11. Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine. Jain MK; Bhat R Neurobiol Dis; 2014 Mar; 63():115-28. PubMed ID: 24269918 [TBL] [Abstract][Full Text] [Related]
12. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease. Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034 [TBL] [Abstract][Full Text] [Related]
13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
14. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158 [TBL] [Abstract][Full Text] [Related]
15. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262 [TBL] [Abstract][Full Text] [Related]
16. Lipid metabolism alterations in the neuronal response to A53T α-synuclein and Fe-induced injury. Sánchez Campos S; Alza NP; Salvador GA Arch Biochem Biophys; 2018 Oct; 655():43-54. PubMed ID: 30098984 [TBL] [Abstract][Full Text] [Related]